Clinical trials: Grade IV Glioma
Recurrent Glioblastoma, Recurrent Gliosarcoma
Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma
This is a phase 0/1 dose-escalation trial to determine the maximum tolerated dose of Mycophenolate Mofetil (MMF) when administered with radiation, in patients with glioblastoma or gliosarcoma.
- Conditions
- Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV, Newly Diagnosed Glioblastoma
- Trial name
- NCT04477200
- Testing
- Mycophenolate Mofetil, Radiation Therapy, Re-resection (as part of standard of care)
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Michigan Rogel Cancer Center
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III
A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of zedoresertib combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and…
- Trial name
- NCT05765812
- Testing
- Zedoresertib, Temozolomide, Radiotherapy
- Where
- 16 sites in United States, Spain and 1 more
- Volunteers
- 116 people
- Sponsor
- Debiopharm International SA
Glioma of Brain
Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse
Open label, non-randomized, mono-center Phase I/II study in subjects with IDH-wildtype WHO grade III / IV glioma at first relapse.
- Trial name
- GLIOMOON (NCT03779230)
- Testing
- L19TNF
- Where
- 3 sites in Switzerland
- Volunteers
- 20 people
- Sponsor
- Philogen S.p.A.
Recurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma
Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM
This phase I trial is to find out the best dose, possible benefits and/or side effects of engineered natural killer (NK) cells containing deleted TGF-betaR2 and NR3C1 (cord blood [CB]-NK-TGF-betaR2-/NR3C1-) in treating patients…
- Conditions
- Recurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma, Supratentorial Gliosarcoma
- Trial name
- NCT04991870
- Testing
- Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Resection
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Glioma
Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas
The purpose of this study is to see if the addition of the investigation drug called pembrolizumab (Keytruda®) to radiation therapy and bevacizumab (Avastin®) is safe and can help with controlling the growth of tumors, in…
- Trial name
- NCT02313272
- Testing
- Hypofractionated Stereotactic Irradiation (HFSRT), Pembrolizumab, Bevacizumab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Astrocytoma, Grade IV, Giant Cell Glioblastoma
Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
Background: A glioblastoma is a tumor in the brain. It is treated with surgery, chemotherapy and radiation therapy. However, most people s tumors come back after therapy.
- Conditions
- Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme, Gliosarcoma
- Trial name
- NCT02709226
- Testing
- Radiation
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme
RATIONALE: Nelfinavir mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells.
- Trial name
- NCT00915694
- Testing
- nelfinavir mesylate, temozolomide, adjuvant therapy
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Glioma
A Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma
This phase I trial will determine safety, dose-limiting toxicities (DLT) and maximum tolerable dose (MTD) of the protease inhibitor, Nelfinavir (NFV), when given with chemoradiotherapy as post-operative therapy for glioblastoma…
- Trial name
- NCT01020292
- Testing
- Nelfinavir
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Glioblastoma
Biomarkers for Prognosis of Glioblastoma (GBM)
The purpose of this study is: 1. To learn if (MMP-2, MMP-9 and NGAL) which are substances found in blood and urine associated with tumors, can be used as tumor markers in the management and treatment of glioblastoma. 2.
- Trial name
- NCT01493219
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Nebraska
Malignant Primary Gliomas, Glioblastoma Multiform (Grade IV Astrocytoma)
5G-EMERALD: Amivantamab in Malignant Brain Tumours
The purpose of this clinical trial is to evaluate the safety and tolerability of amivantamab and to determine the preliminary antitumour activity of amivantamab administered at the recommended Phase 2 dose (RP2D).
- Conditions
- Malignant Primary Gliomas, Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant, Glioblastoma Multiforme (GBM)
- Trial name
- 5G-EMERALD (NCT06632236)
- Testing
- Amivantamab
- Where
- 2 sites in United Kingdom
- Volunteers
- 12 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma
This is a Phase II trial to evaluate the safety, tolerability, efficacy, and PK/ pharmacodynamic profiles of MT027 injected via ICV in participants with recurrent or progressive IDH-wildtype glioblastoma (WHO 2021 CNS Grade 4)…
- Trial name
- GLIOMAX-101 (NCT07386002)
- Testing
- Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3
- Where
- 4 sites in United States, Taiwan
- Volunteers
- 40 people
- Sponsor
- T-MAXIMUM Pharmaceutical Inc
Glioma Glioblastoma Multiforme, High Grade Glioma (III or IV)
Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas
Gliomas are the most common malignant brain tumors, which are often associated with high-grade tumors characterized by an inferior prognosis and low patient survival rates in both children and adults.
- Trial name
- NCT06687681
- Testing
- NK cell therapy
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Marzieh Ebrahimi
Glioblastoma
NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy
This study will assess whole brain samples from glioblastoma patients at autopsy to determine the underlying pathological signatures of tumor treatment fields at autopsy.
- Trial name
- NCT03194971
- Testing
- Tumor samples from patients treated with TTFields at initial diagnosis., Tumor samples from patients treated with TTFields at tumor recurrence.
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical College of Wisconsin
Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype
Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
This phase I trial studies the side effects and best dose of EGFR/IL13Rα2 pool-chimeric antigen receptor (CAR) T cells when given through a thin, flexible tube into the brain (locoregional administration) in treating patients…
- Trial name
- NCT07544992
- Testing
- Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells, Biopsy Procedure, Biospecimen Collection
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- City of Hope Medical Center
Stage III and IV Glioma Patients
CTCs for High Grade Glioma
The purpose of this study is to identify and quantify circulating tumor markers, which are associated with the presence of tumors.
- Trial name
- NCT02558335
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Glioblastoma Multiforme (GBM) WHO Grade IV
Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme
The proposed study is an open-label, single-arm, Phase- II trial to assess the efficacy of cabazitaxel in GBM WHO grade IV patients with a progression during or within 6 months after last temozolomide treatment (Figure 1).
- Trial name
- NCT01866449
- Testing
- Cabazitaxel
- Where
- 3 sites in Germany
- Volunteers
- 24 people
- Sponsor
- University of Ulm
Glioblastoma Multiforme
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
This multi-site, Phase 1/2a clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with…
- Trial name
- NCT02704858
- Testing
- Perillyl alcohol
- Where
- 11 sites in United States
- Volunteers
- 49 people
- Sponsor
- Neonc Technologies, Inc.
R/R Grade 4 Glioma
TH-CAR-027 for Grade 4 Gliomas
This is an open-Label, dose-escalation, multiple administration, exploratory clinical study to evaluate the safety, tolerability, and anti-tumor activity of TH-CART-027 cell injection in subjects with recurrent or progressive…
- Trial name
- NCT07384390
- Testing
- TH-CART-027
- Volunteers
- 21 people
- Sponsor
- Shanghai Tongji Hospital, Tongji University School of Medicine
Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
This phase II trial compares the effect of GI-102 alone and in combination with pembrolizumab given before surgery in treating patients with IDH wildtype glioblastoma and IDH mutated grade 4 astrocytoma that has come back after a…
- Conditions
- Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4, Progressive Glioblastoma, Progressive Gliosarcoma
- Trial name
- NCT07301268
- Testing
- Biospecimen Collection, Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102, Computed Tomography
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Mayo Clinic